Anti-interleukin-6 - Wikipedia
Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. [1] . Hence, anti-IL6 agents have been sought. [2][3][4][5][6] In rheumatoid arthritis they can help patients unresponsive to TNF inhibitors. [7]
UpToDate
Multiple pharmacologic inhibitors (sometimes termed blockers) of IL-6 are commercially available for clinical use, including monoclonal antibodies directed against the IL-6 receptor (IL-6R; eg, tocilizumab, sarilumab, and satralizumab) as well as monoclonal antibodies specific for IL-6 (eg, siltuximab and olokizumab).
Interleukin 6 - Wikipedia
IL-6's role as an anti-inflammatory myokine is mediated through its inhibitory effects on TNF and IL-1 and its activation of IL-1ra and IL-10. There is some early evidence that IL-6 can be used as an inflammatory marker for severe COVID-19 infection with poor prognosis, in the context of the wider coronavirus pandemic. [6]
List of Interleukin inhibitors - Drugs.com
Interleukin inhibitors are immunosuppressive agents which inhibit the action of interleukins. Interleukins are a group of cytokines which are synthesized by lymphocytes, monocytes, macrophages, and certain other cells. They function especially in regulation of …
A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor ... - PubMed
2015年7月1日 · Although IL-6 and its signaling pathways are promising targets, orally available small-molecule drugs specific for IL-6 have not been developed. To discover IL-6 antagonists, we screened our in-house chemical library and identified LMT-28, a novel synthetic compound, as a candidate IL-6 blocker.
Targeting IL-6 trans-signalling: past, present and future prospects
2023年4月17日 · The first selective inhibitor of IL-6 trans-signalling, sgp130, has shown therapeutic potential in various preclinical models of disease and olamkicept, a sgp130Fc variant, had promising...
Translating IL-6 biology into effective treatments - Nature
2020年4月23日 · Pharmacological inhibitors of IL-6 signalling prevent IL-6 from binding to IL-6R by targeting either the cytokine itself or the receptor. b | In the context of disease, IL-6 can have both...
IL-6 抑制剂 - MCE-生物活性分子大师
LMT-28 是一种具有口服活性的通过直接与 gp130 结合而发挥作用的 IL-6 抑制剂。 LMT-28 具有低毒性，并选择性抑制 IL-6 诱导的 STAT3、JAK2 和 gp130 的磷酸化。 Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate)，一种糖皮质激素， 是口服活性的甾体抗炎剂 (SAID)，具有抗炎和免疫调节活性。 Hydrocortisone hemisuccinate 抑制 IL-6 和 IL-3 的生物活性， IC50 值分别为 6.7 和 21.4 μM。 Hydrocortisone hemisuccinate 可用于溃疡性结肠炎 (UC) …
IL-6 in Inflammation, Immunity, and Disease - PMC - PubMed …
IL-6 is a cytokine featuring pleiotropic activity; it induces synthesis of acute phase proteins such as CRP, serum amyloid A, fibrinogen, and hepcidin in hepatocytes, whereas it inhibits production of albumin. IL-6 also plays an important role on acquired immune response by stimulation of antibody production and of effector T-cell development.
Interleukin-6 Receptor Inhibitors for the Treatment of …
Inhibitors of IL-6 action can target either the IL-6 ligand itself or the IL-6 receptor. Tocilizumab is a humanized monoclonal antibody targeting the IL-6 receptor that was approved by the FDA in 2010 as an intravenous formulation for the treatment of RA; it was later approved as a …
- 某些结果已被删除